Regenxbio Inc (RGNX) Stock Price, Quote & News

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 552 8181

Website: www.regenxbio.com

Address:

9804 Medical Center Drive, Rockville, United States

buymoremakemore May. 13 at 7:54 PM

$RGNX 20% gain in 2 weeks is a solid data runup with a war going on. No harm in playing it safe, but if this data blows SRPT out of the water, there should be no sell the news. MC will go up tremendously

0 · Reply

Goatedinvestor May. 13 at 7:43 PM

$RGNX thinking they sell rgx 314 ex us rights for around 1b upfront and royalties to solve their cash problem

0 · Reply

flyinghollaender May. 13 at 7:36 PM

$RGNX i think more volume will come now before closing

0 · Reply

murphylaw May. 13 at 7:24 PM

$RGNX this action is very disappointing. if it is not going up at this point, then more than likely it'll sell on news. I am out. Wish those who are hoping for good news all the best!

0 · Reply

maphere May. 13 at 6:38 PM

$RGNX ABBVIE investing big $$$ into the PH3 wAMD trial, look at the global sites being added and preparing for commercialization. Abbvie doesn't say much at their ER about this but this is where a lot of $$$ is going right now. Hope to hear some news tomorrow. https://clinicaltrials.gov/study/NCT07007065?term=abbv-rgx-314&viewType=Card&rank=5&tab=history&a=60&b=61&compareMode=sideBySide#version-content-panel

3 · Reply

explover May. 13 at 5:09 PM

$RGNX so basically if interim results (n=13) from March 11, 2026 replicate on the pivotal sample (n=30), this goes to $18-24 on day one and then further I suppose we are afraid of a single SAE?

1 · Reply

cold_beef_cake May. 13 at 3:52 PM

$RGNX Not trading like a company that's about to hit it out of the park.

2 · Reply

RobbyAxelrod1 May. 13 at 3:40 PM

$RGNX Sold ill wait for tomorrow usually news seeps in by now doesn't look to good here.

2 · Reply

maphere May. 13 at 2:37 PM

$RGNX Another webinar on the 19th...3 hours long.

1 · Reply

murphylaw May. 13 at 2:24 PM

$RGNX should be $12 by 4PM?

1 · Reply

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

May 6, 2026, 7:05 AM EDT - 7 days ago

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

Mar 26, 2026, 9:00 AM EDT - 6 weeks ago

SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

2026-03-24T15:47:52.000Z - 7 weeks ago

Shareholders Sue RGNX Over Gene Therapy Study Claims

Mar 11, 2026, 12:00 PM EDT - 2 months ago

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

2026-03-11T15:56:10.000Z - 2 months ago

Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial

Mar 11, 2026, 11:45 AM EDT - 2 months ago

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Mar 10, 2026, 1:30 PM EDT - 2 months ago

REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 9:20 AM EDT - 2 months ago

REGENXBIO Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T10:15:30.000Z - 2 months ago

Regenxbio price target lowered to $30 from $32 at H.C. Wainwright

Mar 6, 2026, 11:33 AM EST - 2 months ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA WVE

2026-03-05T20:15:32.000Z - 2 months ago

Regenxbio price target lowered to $17 from $18 at Morgan Stanley

Mar 5, 2026, 2:25 PM EST - 2 months ago

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

2026-03-05T19:15:21.000Z - 2 months ago

Regenxbio price target lowered to $42 from $45 at Stifel

Mar 5, 2026, 8:00 AM EST - 2 months ago

REGENXBIO Earnings Call Transcript: Q4 2025

2026-03-05T12:15:47.000Z - 2 months ago

Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year

Mar 5, 2026, 7:05 AM EST - 2 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 4, 2026, 7:05 AM EST - 2 months ago

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 2, 2026, 5:58 PM EST - 2 months ago

REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses

Mar 2, 2026, 7:05 AM EST - 2 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

2026-02-26T16:07:27.000Z - 2 months ago

Leerink says FDA remarks likely targeted Regenxbio, not uniQure’s program

QURE

Feb 25, 2026, 7:05 AM EST - 2 months ago

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

2026-02-20T16:52:26.000Z - 2 months ago

Court revives Regenxbio, UPenn patent suit against Sarepta, Bloomberg says

SRPT

2026-02-10T14:12:19.000Z - 3 months ago

Regenxbio price target lowered to $32 from $34 at H.C. Wainwright

Feb 9, 2026, 4:13 PM EST - 3 months ago

US FDA declines to approve Regenxbio's rare disease drug

Feb 9, 2026, 4:05 PM EST - 3 months ago

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Jan 29, 2026, 6:06 PM EST - 3 months ago

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

Jan 28, 2026, 7:46 AM EST - 3 months ago

US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28, 2026, 7:30 AM EST - 3 months ago

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

Jan 14, 2026, 1:30 PM EST - 4 months ago

REGENXBIO Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 3:00 PM EST - 4 months ago

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

Dec 18, 2025, 7:05 AM EST - 5 months ago

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 8:30 AM EST - 5 months ago

REGENXBIO Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:05 AM EST - 6 months ago

REGENXBIO to Participate in Upcoming Investor Conference

Nov 11, 2025, 1:20 PM EST - 6 months ago

REGENXBIO Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 6 months ago

REGENXBIO Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 8:00 AM EST - 6 months ago

REGENXBIO Earnings Call Transcript: Q3 2025

Nov 6, 2025, 7:05 AM EST - 6 months ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

Oct 30, 2025, 7:05 AM EDT - 6 months ago

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Oct 29, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

Oct 9, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

Oct 6, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Sep 29, 2025, 7:05 AM EDT - 8 months ago

REGENXBIO Announces Presentation at the World Muscle Society

Sep 8, 2025, 11:30 AM EDT - 8 months ago

REGENXBIO Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 5, 2025, 7:05 AM EDT - 8 months ago

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Aug 18, 2025, 5:00 PM EDT - 9 months ago

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Aug 7, 2025, 8:00 AM EDT - 9 months ago

REGENXBIO Earnings Call Transcript: Q2 2025

Aug 7, 2025, 7:05 AM EDT - 9 months ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 7, 2025, 7:00 AM EDT - 9 months ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Jul 31, 2025, 7:05 AM EDT - 10 months ago

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Jul 10, 2025, 11:54 AM EDT - 10 months ago

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Jun 5, 2025, 8:00 AM EDT - 1 year ago

REGENXBIO Transcript: Status Update

Jun 5, 2025, 7:05 AM EDT - 1 year ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Jun 2, 2025, 7:05 AM EDT - 1 year ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

May 20, 2025, 11:30 AM EDT - 1 year ago

REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 19, 2025, 4:05 PM EDT - 1 year ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

buymoremakemore May. 13 at 7:54 PM

0 · Reply

Goatedinvestor May. 13 at 7:43 PM

$RGNX thinking they sell rgx 314 ex us rights for around 1b upfront and royalties to solve their cash problem

0 · Reply

flyinghollaender May. 13 at 7:36 PM

$RGNX i think more volume will come now before closing

0 · Reply

murphylaw May. 13 at 7:24 PM

$RGNX this action is very disappointing. if it is not going up at this point, then more than likely it'll sell on news. I am out. Wish those who are hoping for good news all the best!

0 · Reply

maphere May. 13 at 6:38 PM

3 · Reply

explover May. 13 at 5:09 PM

$RGNX so basically if interim results (n=13) from March 11, 2026 replicate on the pivotal sample (n=30), this goes to $18-24 on day one and then further I suppose we are afraid of a single SAE?

1 · Reply

cold_beef_cake May. 13 at 3:52 PM

$RGNX Not trading like a company that's about to hit it out of the park.

2 · Reply

RobbyAxelrod1 May. 13 at 3:40 PM

$RGNX Sold ill wait for tomorrow usually news seeps in by now doesn't look to good here.

2 · Reply

maphere May. 13 at 2:37 PM

$RGNX Another webinar on the 19th...3 hours long.

1 · Reply

murphylaw May. 13 at 2:24 PM

$RGNX should be $12 by 4PM?

1 · Reply

buymoremakemore May. 12 at 11:45 PM

$RGNX Rarely any bears on here coming into data readout. Short float 15%. Not bad

0 · Reply

Timefortendies77 May. 12 at 10:55 PM

$RGNX Hi RGNX ---it's your pals over at $BHVN. What's the word on getting your drug reassessed given the change in FDA leadership?

2 · Reply

Timefortendies77 May. 12 at 10:53 PM

$BHVN Remember this tweet? @US_FDA exploring path forward for therapies that received CRLs $BHVN , $RGNX , Sydnexis held meetings w FDA’s chief counsel, Sean Keveney, following high-profile regulatory setbacks. Such meetings are highly unusual, writes BioCentury Washington Editor https://x.com/jeff_cranmer/status/2039127714599440671

0 · Reply

murphylaw May. 12 at 5:59 PM

$RGNX Epic pop in store tomorrow. Buckle up!

0 · Reply

Wolfman5960 May. 12 at 4:57 PM

$RGNX Looks like Makary is officially out and Kyle Diamantas will be the acting commissioner. https://www.politico.com/news/2026/05/12/makary-fda-resign-white-house-00916014

2 · Reply

Find_the_Cure May. 12 at 4:03 PM

$RGNX This should be up HUGELY since the AI stocks are seeing outflows today. It’s now or never.

0 · Reply

maphere May. 12 at 2:15 PM

$RGNX Good sign, coming May 20th: Parent Project Muscular Dystrophy Please join PPMD for a community webinar on May 20th at 1:00 PM ET with REGENXBIO, who will share topline results from the pivotal portion of the AFFINITY DUCHENNE trial evaluating RGX-202, the company’s investigational gene therapy for #Duchenne #musculardystrophy. REGENXBIO will review key findings from the pivotal study, including data on microdystrophin expression and interim safety and functional outcomes. Learn more, submit questions in advance, and register now: https://www.facebook.com/plugins/post.php?href=https%3A%2F%2Fwww.facebook.com%2Fparentprojectmd%2Fposts%2Fpfbid06dycaiyWeCdv52K75Diu7LVv1bkfk3mznDRc7uyWdg3RSYwCjAgRRpm3wDFAgpHql&show_text=true&width=500

3 · Reply

derkatch83 May. 12 at 4:38 AM

$RGNX guess yesterday’s drop was a reaction for CEO selling shares. But it was the automatic planned transaction, so no bearish signal to me

3 · Reply

Find_the_Cure May. 11 at 7:45 PM

$RGNX LOFL

0 · Reply

Find_the_Cure May. 11 at 7:03 PM

$RGNX what a turd

0 · Reply

OppieMax May. 11 at 5:12 PM

$RGNX Am I buying this ahead of Thursday? Seems like a good risk/reward setup for a small punt, no?

2 · Reply

Find_the_Cure May. 11 at 4:25 PM

$RGNX WTF happened here today?

1 · Reply

Market Cap	520.30M
Revenue (ttm)	170.44M
Net Income (ttm)	-193.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-113.75%
Debt to Equity Ratio	0.00

Volume	1,468,195
Avg Vol	808,860
Day's Range	N/A - N/A
Shares Out	51.62M
Stochastic %K	60%
Beta	1.12
Analysts	Strong Sell
Price Target	$29.25